Celldex Therapeutics

Yahoo Finance • 23 days ago

Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the best small cap stocks to buy with huge upside potential. Barclays lifted the price target on Celldex Therapeutics, Inc. (NASDAQ:CLDX) to $24 from $21 on December 17 and reaffirmed an E... Full story

Yahoo Finance • last month

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism

No advanced therapies approved to treat ColdU and SD—diseases of misery that dramatically impact all aspects of patient lifeBarzolvolimab is the only drug in development to demonstrate clinical benefit in patients in ColdU and SD in a larg... Full story

Yahoo Finance • 2 months ago

Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Strong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating rapid, profound improvement in UCT7 scores with sustained disease control post treatment and s... Full story

Yahoo Finance • 2 months ago

Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished global healthcare executive with 30... Full story

Yahoo Finance • 2 months ago

Celldex to Present at Upcoming Investor Conferences

HAMPTON, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Confer... Full story

Yahoo Finance • 2 months ago

Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition

--Data from Phase 1 Study in healthy volunteers presented at CIA Biennial Symposium-- HAMPTON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today positive data from the ongoing Phase 1 study of CDX-622, a nove... Full story

Yahoo Finance • 3 months ago

Celldex Therapeutics (CLDX): Evaluating Valuation After Barclays' Underweight Rating and Industry Concerns

Barclays’ recent launch of coverage on Celldex Therapeutics (CLDX) assigned the stock an Underweight rating, drawing investor focus to both sector competition and questions about the safety profile of barzolvolimab. See our latest analysi... Full story

Yahoo Finance • 3 months ago

Barclays initiates coverage on U.S. small & mid-cap biotech stocks

Investing.com -- Momentum in small and mid-cap (SMID) biotechnology has accelerated recently, with investors rewarding companies bringing new mechanisms and dosing advantages to market. Over the past six months, the Nasdaq Biotechnology I... Full story

Yahoo Finance • 4 months ago

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

HAMPTON, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating rapid and strong efficacy regardless of baseline immunoglobulin E (IgE) levels in patients with chronic spontaneous urticaria... Full story

Yahoo Finance • 4 months ago

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

HAMPTON, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that management will participate in a fireside chat today, September 9th, 2025, at the Morgan Stanley 23rd Annual Global Healthcare Conf... Full story

Yahoo Finance • 5 months ago

Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma

Company Logo The global chronic inducible urticaria (CIndU) market is experiencing significant transformation due to rising prevalence, advancements in diagnostics, and targeted immunotherapies. Affecting 0.1% to 3% of the population, CIn... Full story

Yahoo Finance • 5 months ago

Celldex stock falls as barzolvolimab fails in EoE despite Cantor's positive view

Investing.com - Celldex Therapeutics (NASDAQ:CLDX), a $1.6 billion market cap biotech company currently trading near $24, reported negative results from its barzolvolimab study in eosinophilic esophagitis (EoE), despite Cantor Fitzgerald... Full story

Yahoo Finance • 5 months ago

Biggest stock movers Wednesday: FUTU, ALC, and more

[Candlestick chart and data of financial market.] tadamichi Stock futures edged lower early Wednesday as investors awaited the release of the Federal Reserve’s July meeting minutes for fresh clues on the path of interest rates. Here are... Full story

Yahoo Finance • 5 months ago

Celldex slides after Barzolvolimab hits target but fails to improve EoE symptoms in phase 2 trial

[Scientist analyze biochemical samples in advanced scientific laboratory. Medical professional use microscope look microbiological developmental of viral. Biotechnology research in science lab.] Celldex Therapeutics (NASDAQ:CLDX [https://... Full story

Yahoo Finance • 5 months ago

These stocks are moving in today's after hours session

After the conclusion of the US market's regular session on Tuesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE... Full story

Yahoo Finance • 5 months ago

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal tractProfound mast cell depletion did not result in improved clinical outcomes providing direct evidence that mast cell... Full story

Yahoo Finance • 5 months ago

Celldex Therapeutics Inc (NASDAQ:CLDX) Q2 2025 Earnings: Revenue Misses, EPS Narrowly Beats Amid Strong Pipeline Progress

CELLDEX THERAPEUTICS INC (NASDAQ:CLDX [https://www.chartmill.com/stock/quote/CLDX]) REPORTS Q2 2025 EARNINGS: REVENUE MISSES ESTIMATES, EPS NARROWLY BEATS EXPECTATIONS Celldex Therapeutics Inc released its second-quarter 2025 financial re... Full story

Yahoo Finance • 5 months ago

Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Strong execution and continued progress across pipeline Unprecedented data delivered from Phase 2 CSU study demonstrating profound, sustained complete response and improved quality of life 7 months after completion of barzolvolimab dosing... Full story

Yahoo Finance • 6 months ago

Jasper Therapeutics' SWOT analysis: briquilimab stock faces pivotal moment

Jasper Therapeutics, Inc. (NASDAQ:JSPR), a biopharmaceutical company focused on developing treatments for chronic urticaria, stands at a critical juncture as it navigates recent setbacks and prepares for crucial data readouts. With a marke... Full story

Yahoo Finance • 7 months ago

Celldex stock price target maintained at $50 by H.C. Wainwright

H.C. Wainwright reiterated its Buy rating and $50.00 price target on Celldex Therapeutics (NASDAQ:CLDX) following the company’s presentation of 76-week data from its Phase 2 trial of barzolvolimab in chronic spontaneous urticaria (CSU).... Full story